Table 4.
Logistic Regression Analysis for the Odds of Chemotherapy-Related Hospitalizations Within 6 Months of Therapy Initiation Among Patients With Early-Stage Breast Cancer Older Than Age 65 Years
| Variable | OR* | 95% CI |
|---|---|---|
| Chemotherapy regimen | ||
| TC | Reference | |
| AC | 1.50 | 1.08 to 2.08 |
| TAC | 2.43 | 1.61 to 3.68 |
| AC + T | 1.49 | 1.04 to 2.14 |
| ddAC + P | 1.45 | 0.99 to 2.13 |
| AC + wP | 1.80 | 1.18 to 2.76 |
| Age at diagnosis, years | ||
| 66-70 | Reference | |
| 71-75 | 1.39 | 1.13 to 1.70 |
| 76-80 | 1.39 | 1.06 to 1.83 |
| > 80 | 2.72 | 1.75 to 4.23 |
| Year of diagnosis | ||
| 2003 | Reference | |
| 2004 | 0.92 | 0.69 to 1.22 |
| 2005 | 0.93 | 0.69 to 1.25 |
| 2006 | 1.07 | 0.79 to 1.45 |
| 2007 | 0.92 | 0.67 to 1.25 |
| Race/ethnicity | ||
| White | Reference | |
| African American | 1.04 | 0.74 to 1.45 |
| Hispanic | 1.05 | 0.74 to 1.48 |
| Other | 1.91 | 1.21 to 3.04 |
| Stage | ||
| Localized | Reference | |
| Regional | 1.22 | 0.99 to 1.51 |
| ER/PR | ||
| Negative | Reference | |
| Positive | 0.94 | 0.74 to 1.21 |
| Unknown | 0.61 | 0.36 to 1.04 |
| Surgery | ||
| Mastectomy | Reference | |
| Lumpectomy | 0.92 | 0.76 to 1.11 |
| Use of G-CSF primary prophylaxis | 0.85 | 0.69 to 1.04 |
| Charlson comorbidity index | ||
| 0 | Reference | |
| 1 | 1.48 | 1.19 to 1.84 |
| ≥ 2 | 2.70 | 2.03 to 3.59 |
NOTE. Bold font indicates statistical significance.
Abbreviations: AC, doxorubicin and cyclophosphamide; AC + T, doxorubicin and cyclophosphamide followed or preceded by docetaxel; AC + wP, doxorubicin and cyclophosphamide followed or preceded by weekly paclitaxel; ddAC + P, dose-dense doxorubicin and cyclophosphamide followed or preceded by paclitaxel; ER, estrogen receptor; G-CSF, granulocyte colony-stimulating factor; OR, odds ratio; PR, progesterone receptor; TAC, docetaxel, doxorubicin, and cyclophosphamide; TC, docetaxel and cyclophosphamide.
Adjusted for the variables listed in Table 1 in addition to SEER region and Census variables